As mentioned above, despite the theoretical possibility that GH-RH agonists could stimulate prostate cell proliferation through GH/IGF-1 signaling, in vivo studies have paradoxically shown inhibitory effects on tumor growth due to receptor downregulation. This evidence concerns the gene GH1 and neoplasm.